In a fruitful 2 year collaboration with CCI, We Discover iteratively designed and delivered a fully customised and globally unique solution that met ZERO's design specifications for analysing and visualising cancer genome data. The new system is secure, scalable, and user-friendly, allowing for the seamless integration of dozens of diverse data sources. We designed a streamlined and intuitive user interface to simplify the analysis of these complex data.  Our engagement consisted of the following outputs and deliverables:

1. Product Management

• Ran workshops to brainstorm for solution and objectives,  frame the platform’s vision, define goals and objectives,
• Mapped the to-be/future state and create a product roadmap
• Collaborated to map user stories
• Refining scope & requirements - to achieve desired outcomes/solutions
• Prioritise product backlog items
• Working with developers on technical feasibility of solutions etc
• Scrum framework - 2 week sprints

2. Product Design

• Conducted discovery through research and interviews with users to gain an in-depth understanding of the current process
• Created a process map to visualise as-is state to be able to identify problems in the current state
• Conducted series of workshops and ideation sessions
• Set a weekly cadence of design-feedback-iterate (needs constant validation if data representation etc. or how we understand it are correct)
• Design sprints have to be ahead of dev sprints 
• Prototype to present to stakeholders & gather feedback
• Usability testing to get feedback for design iterations & improvements
• Design system?
• Design quality assurance

‍

The design and delivery of ZeroDash has streamlined the data matching, interpretation, and reporting system, significantly reducing hands-on analysis time from 22 hours to 6.5 hours. ZeroDash has also reduced the number of data analysis queries needed to interpret each case. Other significant improvements include:

• Streamlined data curation and interpretation, resulting in a 50% improvement in reporting efficiency and turnaround times.
• Reduced time spent on manual tasks, allowing for the curation of more patients and the ability to undertake additional research projects while keeping up with field developments.
• Streamlined training processes for new staff joining the ZERO program, facilitating rapid scaling on demand.
• The ability to conduct curation training to upskill wider CCI research staff and students, ultimately utilizing multi-omics approaches to address their own research questions.
• Future potential for CCI to offer paid training courses and software licensing opportunities in integrated multi-omics analysis and data curation.
• A fit-for-purpose software solution capable of transitioning from research to clinical-grade testing and reporting in the future.
• Improved risk profile of the program, ultimately benefiting CCI and KCC, due to a higher degree of automation, resulting in reduced human error and more reliable and robust reporting.
• Facilitation of more rapid and meaningful interpretation of data sets, leading to greater clinical impact.

‍